En studie for å evaluere EMB 001 i emner med kokainbruksforstyrrelse
En fase 2, randomisert, dobbeltblind, placebokontrollert, parallell gruppe, studie for å evaluere sikkerheten og effekten av EMB 001 hos personer med moderat til alvorlig kokainbruksforstyrrelse
EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone (Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®; now marketed as oxazepam (generic) only).
This is a Phase 2 study in approximately 80 adult subjects with moderate-to-severe Cocaine Use Disorder (CUD).
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
This study is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, study to compare the safety and efficacy of EMB-001 with a placebo control in approximately 80 subjects with moderate-to-severe CUD. Subjects will receive investigational medicinal product (IMP) during a 12-week, double-blind Treatment Period (Week 2 through Week 13) and a 1-week, double-blind Taper Period (Week 14).
After undergoing study procedures during the Screening and Baseline Periods, subjects who meet inclusion and exclusion criteria will then be randomized in a 1:1 ratio (n=40/arm) to one of the following for the Treatment Period (weeks 2 - 13) on Study Day 8:
- EMB-001 720 mg metyrapone/24 mg oxazepam mg BID, for a total daily dose of 1440 mg metyrapone and 48 mg oxazepam (Active Group)
- Placebo BID, (Placebo Group)
During the Taper Period (week 14), subjects in the Active Group will receive EMB-001 240/8 mg BID; and the Placebo Group will continue to receive placebo. Both groups will change from taking three capsules BID (twice daily) to one capsule BID (twice daily).
There will be a follow-up visit for safety assessments at Week 18.
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
California
-
San Diego, California, Forente stater, 92092
- Pacific Treatment and Research Center, Department of Psychiatry, University of California, San Diego, School of Medicine
-
-
Florida
-
Miami, Florida, Forente stater, 33161
- Segal Trials
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- U PENN- Perelman School of Medicine
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29403
- Medical University of South Carolina
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
- Provide written informed consent prior to any study procedures
- 18 to 65 years of age
- DSM-5 diagnosis of moderate-to-severe CUD
- Seeking treatment for CUD. Subjects with past rehabilitation attempts are eligible if the most recent rehabilitation attempt ended at least 30 days prior to Screening
- Female subjects must be of non-childbearing potential
- Male subjects must agree to use accepted contraceptive regimens during the study and for at least 90 days after the last dose of the study drug
Key Exclusion Criteria:
- Any significant current medical conditions
- Known hypersensitivity to or intolerance of oxazepam, metyrapone, or any benzodiazepine, or severe hypersensitivity reaction (e.g., angioedema) to any drug
- Heightened likelihood of having adrenal insufficiency in the investigator's or designees' opinion
- Current court-mandated treatment requirement for a substance-use disorder
- Current DSM-5 moderate-to-severe substance use disorder, other than CUD, tobacco or caffeine
- Current DSM-5 opioid or benzodiazepine use disorder of any severity
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Aktiv komparator: EMB-001 Active
EMB-001 Combination product of 720 mg metyrapone/24 mg oxazepam mg by mouth twice per day for 12 weeks followed by a 1 week taper |
720 mg metyrapone/24 mg oxazepam mg BID |
|
Placebo komparator: EMB-001 Placebo
EMB-001 Placebo by mouth twice per day for 12 weeks followed by a 1 week taper |
Inactive comparator |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Continuous Abstinence From Cocaine Use
Tidsramme: Week 11 to Week 13
|
The Primary Endpoint is the Percentage of Subjects That Successfully Achieve Abstinence From Cocaine During the Last Three Weeks of Treatment using the Timeline Follow Back; days of abstinence, confirmed by Urine benzoylecgonine (BE) |
Week 11 to Week 13
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Cocaine-use Days (Weekly Average)
Tidsramme: Final 3 weeks of treatment (Weeks 11, 12 and 13 for subjects who complete the trial fully, but whichever weeks are the final 3 weeks for subjects who do not fully complete the trial) compared to the 28 days prior to screening.
|
Weekly cocaine use days 28 days prior to Screening (Time Line Follow-back (TLFB) only) to weekly use days during final 3 weeks of treatment (TLFB confirmed by urine BE) |
Final 3 weeks of treatment (Weeks 11, 12 and 13 for subjects who complete the trial fully, but whichever weeks are the final 3 weeks for subjects who do not fully complete the trial) compared to the 28 days prior to screening.
|
|
Reduction in Total Cocaine Craving Questionnaire-Brief Score
Tidsramme: Baseline to Week 13 (Day 91)
|
The Cocaine Craving Questionnaire-Brief (CCQ-B) assesses current cocaine craving in routine clinical practice. The CCQ-B is a 10 item questionnaire and items are scored on a one to seven scale. Total responses are then divided by 10 to achieve a total craving score between 1.0 (least craving) to 7.0 (most craving). |
Baseline to Week 13 (Day 91)
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Samarbeidspartnere
Samarbeidspartnere
Etterforskere
Etterforskere
- Studiestol: Bruce McCarthy, MD, Embera NeuroTherapeutics, Inc.
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
Andre studie-ID-numre
- ERL-003
- 5U01DA038879-03 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Every three months, the NIDA DSMB will convene to review the overall safety data, as well as data on safety summarized by treatment condition. As per NIH guidelines, the objective of these reviews will be to determine whether continued conduct of the trial poses any undue risk for participants. Blinded data tables, figures and/or listings will be provided to the Data Safety Monitoring Board (DSMB).
IPD-delingstidsramme
Every three months- blinded results
Tilgangskriterier for IPD-deling
A DSMB report is prepared an submitted via NIDA
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .